NeurAxis, Inc. (NRXS) AI Stock Analysis

• Market Cap: $28.02M
• Dividend Yield: N/A
• Average Volume (3M): 58.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 36.89%
• EPS Growth: 43.58%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 10,652,812
• 10 Day Avg. Volume: 29,678
• 30 Day Avg. Volume: 58,152
• PEG Ratio: 0.04
• Price to Book (P/B): 7.86
• Price to Sales (P/S): 6.05
• P/FCF Ratio: -2.65
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 7.89
• Enterprise Value/Gross Profit: 9.36
• Enterprise Value/Ebitda: -3.56
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.92
• Revenue Forecast (FY): $3.97M

• Rating: 44 Neutral
• Price Target: $2.50 ▼(-17.49% Downside)

NeurAxis faces significant financial challenges with negative equity and cash flow issues, which are the most impactful factors. While there is revenue growth and strategic planning for future expansion, the current financial instability and valuation concerns weigh heavily on the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for NeurAxis' products, enhancing its market position and supporting future expansion.

FDA Clearance

FDA clearance expands NeurAxis' market reach, allowing access to new patient demographics and supporting long-term revenue growth.

Veterans Affairs Contract

The VA contract provides access to a large patient base, enhancing NeurAxis' commercial pathway and supporting sustained growth.

Negative Factors

Negative Equity

Negative equity indicates financial instability, limiting NeurAxis' ability to invest in growth and posing long-term financial risks.

Cash Flow Challenges

Persistent cash flow issues hinder NeurAxis' operational flexibility and ability to fund future initiatives, impacting long-term viability.

Reimbursement Challenges

Reimbursement challenges restrict market penetration, affecting revenue potential and delaying the realization of strategic goals.

NeurAxis, Inc. Business Overview & Revenue Model

Company Description

NeurAxis, Inc. (NRXS) is a biotechnology company focused on developing innovative therapies for neurological disorders. The company specializes in the research and commercialization of advanced medical devices and treatment solutions that target a range of conditions, including chronic pain, epilepsy, and other neurological diseases. NeurAxis aims to improve patient outcomes by leveraging cutting-edge technology and scientific expertise to create effective and safe therapeutic options.

How the Company Makes Money

NeurAxis generates revenue primarily through the sale of its medical devices and therapeutic solutions, which are often covered by insurance providers. Key revenue streams include direct sales to hospitals and clinics, partnerships with healthcare systems, and licensing agreements for its proprietary technologies. Additionally, the company may receive funding through governmental grants and research subsidies aimed at advancing its product development. Strategic collaborations with pharmaceutical companies and research institutions also contribute to its earnings, as they often involve shared development costs and royalties on future sales.

NeurAxis, Inc. Financial Statement Overview

Summary

NeurAxis shows revenue growth but faces significant financial challenges. The company has negative equity, high leverage, and negative cash flows, indicating substantial financial risk.

Income Statement

NeurAxis has experienced revenue growth from 2023 to 2024, but its profitability remains a concern. The gross profit margin has stayed relatively stable, but net income is deeply negative, indicating significant losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. While the revenue growth is a positive sign, the company struggles with high operating losses.

Balance Sheet

The balance sheet shows critical weaknesses, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged. The equity ratio is also concerning, suggesting financial instability. Overall, the balance sheet reflects significant financial risk.

Cash Flow

Cash flow analysis reveals that NeurAxis is burning cash, with negative operating and free cash flows. The company has improved its financing cash flow, which may help sustain operations temporarily. However, the free cash flow to net income ratio is unfavorable, indicating poor cash management relative to earnings. While there's some improvement in cash inflows, the cash flow situation remains a challenge.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.36M	2.69M	2.46M	2.68M	2.72M	1.93M
Gross Profit	2.84M	2.32M	2.16M	2.39M	2.25M	1.45M
EBITDA	-7.45M	-7.90M	-9.23M	-4.33M	-2.95M	-3.61M
Net Income	-7.54M	-8.24M	-14.63M	-4.78M	-3.03M	-3.73M
Balance Sheet
Total Assets	5.78M	4.76M	509.50K	1.48M	760.48K	2.79M
Cash, Cash Equivalents and Short-Term Investments	4.38M	3.70M	78.56K	253.70K	320.86K	1.90M
Total Debt	478.43K	473.40K	224.26K	598.82K	439.27K	311.49K
Total Liabilities	3.49M	2.69M	1.91M	7.05M	1.59M	1.15M
Stockholders Equity	2.28M	2.07M	-1.40M	-5.57M	-825.66K	1.64M
Cash Flow
Free Cash Flow	-6.28M	-6.13M	-6.77M	-2.36M	-2.24M	-4.17M
Operating Cash Flow	-6.26M	-6.10M	-6.69M	-2.30M	-2.23M	-4.14M
Investing Cash Flow	-25.29K	-27.78K	-71.78K	-61.20K	-1.39K	-27.72K
Financing Cash Flow	10.40M	9.74M	6.59M	2.29M	661.10K	6.05M

NeurAxis, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXS, the sentiment is Negative. The current price of 3.03 is above the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.85, and above the 200-day MA of 2.52, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.29 is Neutral, neither overbought nor oversold. The STOCH value of 54.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRXS.

NeurAxis, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IGC	47 Neutral	$35.78M	-4.85	-83.34%	―	-6.51%	58.31%
NRXS	44 Neutral	$28.02M	―	-3071.15%	―	36.89%	43.58%
PASG	44 Neutral	$24.14M	―	-87.18%	―	―	38.42%
NERV	34 Underperform	$25.67M	2.47	―	―	―	-323.61%

NeurAxis, Inc. Corporate Events

NeurAxis Expands Stock Offering to $6.27 Million

NeurAxis, Inc. has received FDA 510(k) clearance for its PENFS technology to treat functional abdominal pain associated with functional dyspepsia and related nausea symptoms in patients aged 8 and older. This clearance marks the first FDA approval for treating functional dyspepsia in adults, potentially expanding the company’s market reach. Additionally, on August 29, 2025, NeurAxis entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC to sell common stock, initially priced at $3.3 million, which was later increased to $6.27 million as of October 23, 2025. However, no shares were sold under this agreement by that date.